October 25, 2019
Macleods Pharma USA Inc is recalling nearly 32,000 bottles of pioglitazone hydrochloride tablets because of superpotency concerns. The recall was included in the October 23, 2019, US Food and Drug Administration (FDA) Enforcement Report.
The recall affects 30-count bottles of pioglitazone hydrochloride tablets, 15 mg (NDC 33342-054-07), from lot BPF901A (Exp. 12/21). The product was sent to eight distributors that may have further distributed the medication.
Macleods Pharma initiated the recall September 23, 2019. On October 11, 2019, the FDA designated the recall Class II, communicating use of the affected drug may cause temporary or medically reversible adverse health consequences or a remote possibility of serious harm.
Pioglitazone is a prescription medication used to treat patients with type 2 diabetes.